IRIS
BONATI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.435
AS - Asia 3.117
EU - Europa 2.017
SA - Sud America 299
AF - Africa 142
Continente sconosciuto - Info sul continente non disponibili 34
OC - Oceania 7
Totale 9.051
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.334
SG - Singapore 1.096
CN - Cina 1.010
VN - Vietnam 426
IT - Italia 375
IE - Irlanda 310
SE - Svezia 273
FI - Finlandia 260
DE - Germania 242
BR - Brasile 232
UA - Ucraina 216
HK - Hong Kong 203
TR - Turchia 109
BD - Bangladesh 101
NL - Olanda 99
ZA - Sudafrica 86
CA - Canada 76
FR - Francia 65
GB - Regno Unito 54
IN - India 39
JP - Giappone 38
RU - Federazione Russa 29
CI - Costa d'Avorio 27
AR - Argentina 25
AT - Austria 16
ES - Italia 16
BE - Belgio 15
IQ - Iraq 13
KR - Corea 13
EC - Ecuador 12
MX - Messico 12
PL - Polonia 10
CL - Cile 8
CZ - Repubblica Ceca 8
ID - Indonesia 8
LT - Lituania 7
MA - Marocco 7
PK - Pakistan 7
SA - Arabia Saudita 7
VE - Venezuela 7
AU - Australia 6
DZ - Algeria 6
BO - Bolivia 4
CO - Colombia 4
EE - Estonia 4
IR - Iran 4
JO - Giordania 4
KG - Kirghizistan 4
PH - Filippine 4
PT - Portogallo 4
PY - Paraguay 4
TW - Taiwan 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
KE - Kenya 3
RO - Romania 3
TN - Tunisia 3
AM - Armenia 2
CH - Svizzera 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
LV - Lettonia 2
LY - Libia 2
MN - Mongolia 2
MY - Malesia 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
SC - Seychelles 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CU - Cuba 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
ML - Mali 1
MZ - Mozambico 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
SV - El Salvador 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.018
Salva come PNG Salva come JPEG
Città #
Singapore 537
San Jose 347
Chandler 326
Jacksonville 322
Dublin 309
Ashburn 284
Beijing 265
Santa Clara 263
Hong Kong 193
Dallas 150
Council Bluffs 134
Nanjing 116
Ho Chi Minh City 112
Boardman 106
Ann Arbor 105
Hanoi 105
Parma 98
Izmir 91
Dearborn 87
Johannesburg 84
San Mateo 71
Princeton 70
Los Angeles 58
Lauterbourg 55
New York 53
Toronto 51
Jinan 49
Wilmington 47
Hebei 41
Munich 41
Shenyang 40
Bologna 39
Hefei 36
Tokyo 36
Shanghai 32
Helsinki 31
Des Moines 30
Nanchang 30
Abidjan 27
Kunming 27
São Paulo 27
Moscow 26
Da Nang 23
Columbus 21
Milan 21
Changsha 19
Guangzhou 19
Düsseldorf 18
Haiphong 18
Woodbridge 17
Tianjin 16
Brussels 15
Buffalo 15
Montreal 15
Turku 14
Zhengzhou 14
Amsterdam 13
London 13
Nuremberg 13
Pittsburgh 13
Falls Church 12
Atlanta 11
Fremont 11
Grafing 11
Haikou 11
Brooklyn 10
Chennai 10
Kocaeli 10
Orem 10
Rio de Janeiro 10
Rome 10
Seattle 10
Taizhou 10
The Dalles 10
Hải Dương 9
Jiaxing 9
Lanzhou 9
Leawood 9
Vienna 9
Chicago 8
Denver 8
Fuzhou 8
Houston 8
Seoul 8
Warsaw 8
Baghdad 7
Boston 7
Bremen 7
Chengdu 7
Hangzhou 7
Phoenix 7
Poplar 7
Redmond 7
Trezzano Sul Naviglio 7
Biên Hòa 6
Borås 6
Can Tho 6
Falkenstein 6
Frankfurt am Main 6
Modena 6
Totale 5.586
Salva come PNG Salva come JPEG
Nome #
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma 313
MEK1/2 KINASES DISABLE THE TUMOR SUPPRESSOR FUNCTIONS OF NATIVE BCR AND ABL1 KINASES TO IMPAIR ANTICANCER DRUGS’ RESPONSIVENESS IN TKI-RESISTANT PHILADELPHIA POSITIVE LEUKEMIAS 274
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH+-LEUKEMIA 257
Acenaphthenequinone thiosemicarbazone and its transition metal complexes: synthesis, structure, and biological activity. 169
Early proinflammatory activation of renal tubular cells by normal and pathologic IgG 158
Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL 156
Elevated telomerase activity, minimal telomere loss in cord blood long-term cultures with extensive stem cell replication 155
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 151
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH plus -LEUKEMIA 148
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis. 146
Biochemical, Immunological, and Molecular Markers of Hemopoietic Precursor Cells. 142
p73 and p53 pathway in human breast cancers. 140
Targeting the cancer initiating cell: the ultimate target for cancer therapy. 139
Treatment with Arsenic Trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells 138
A micro-mechanically motivated model for the strength of heat-treated glass 136
Emerging MEK inhibitors 133
T cell receptor genes: a glance at normal and malignant hematopoiesis. 131
Emerging Raf inhibitors 130
Arsenic Trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells 129
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent anti-tumor activity in vivo against human multiple myeloma xenograft model. 128
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts 126
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. 125
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 123
MDM2 inhibition synergistically enhances cytotoxicity of MEK1 inhibitor and Arsenic Trioxide (ATO) in AML blasts that retain a functional p53 pathway 122
Detection of the common acute lymphoblastic leukaemia antigen (CALLA) on B cells from human fetal tissues. A multiple phenotypic characterization. 122
Discordant expression of terminal transferase and T cell receptor beta chain in fetal and pediatric thymocytes. 122
Arsenic Trioxide in hematological malignancies: the new discovery of an ancient drug. 121
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. 121
Terminal deoxynucleotidyl transferase (TdT) levels in hairy cell leukemia. 120
Ph1-positive acute myelocytic leukemia with high TdT levels. 120
Calibration of the Statistical-Interference Factors for the Design of Tempered Structural Glass 119
Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. 119
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 119
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia 118
Human T-cell receptor alpha chain gene during ontogeny 118
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia 118
T-cell receptor beta-chain gene rearrangement and expression during human thymic ontogenesis. 115
Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. 115
Su di un caso di sclerodermia associato ad aplasia midollare globale. 115
Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. 113
MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors 111
Synthesis, characterisation, X-ray structure and biological activity of three new 5-formyluracil thiosemicarbazone complexes 109
Expression of TCR beta chain gene N-diversity is not an early event in human thymic ontogeny 108
Terminal deoxynucleotidyl transferase: a nuclear marker of hemopoietic precursors. Biochemical, immunological and clinical aspects. 107
Espressione degli antigeni CD1a, CD1b, CD1c in timo umano a diverse eta' dello sviluppo. 106
Synthesis, structure, spectroscopic properties and biological activity of mixed diorganotin(IV) complexes containing pyridine-2-carbaldehyde thiosemicarbazonato and diphenyldithiophosphinato ligands. 104
Synthesis, spectroscopic characterization and biological properties of new natural aldehydes thiosemicarbazones 102
Valutazione dell'attivita proliferativa delle cellule emopoietiche nelle sindromi preleucemiche. 102
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4. 102
Hemopoiesis during human fetal life. Present knowledge and future prospects. 101
Terminal deoxynucleotidyl transferase (TDT) expression correlates with the presence of N regions during human thymic ontogeny 100
La linfoadenopatia angio-immunoblastica: Osservazioni cliniche, patologiche ed immunologiche su di un caso. 100
Phorbol ester-induced PKC{epsilon} down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation. 100
Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers. 97
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. 97
La mielofibrosi idiopatica asplenomegalica. Osservazioni cliniche e considerazioni su cinque casi. 95
The fine structure of HNK-1 (Leu7) positive cells. A study using an immunoperoxidase technique. 95
Phenotype of the terminal transferase-positive cells in human foetal liver and bone-marrow: analysis with monoclonal antibodies. 95
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways 95
Terminal deoxynucleotidyl transferase-positive B cell precursors in fetal lymph nodes and extrahemopoietic tissues. 94
Terminal deoxynucleotidyl transferase in human fetal tissues. 94
TCR beta chain expression during human thymic development. 93
Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival. 91
The combination of MEK inhibitors and Arsenic Trioxide triggers in vitro and in vivo synergistic cytotoxicity in multiple myeloma through multiple signaling pathways 89
Selective Expression and Constitutive Phosphorylation of SHC Proteins in the CD34+ Fraction of Chronic Myelogenous Leukemias. 86
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 86
Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukaemia with unusual phenotype. 85
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. 84
Terminal deoxynucleotidyl transferase (TdT) in human foetuses. An immunofluorescent and biochemical study. 81
Regulation of proliferation and cytokine expression of bone marrow fibroblasts: role of c-myb. 80
Leu-7-positive cells with monocyte phenotype show different ultrastructural features in comparison to Leu-7-positive cells with T-cell phenotype. 79
Medicina molecolare: nuovi strumenti per la conoscenza e la cura delle patologie dell'uomo. 78
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. 76
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. 75
Combined Treatment with the Mek Inhibitor PD0325901 and Arsenic Trioxide Has Potent Antitumor Activity in Vivo against Human Multiple Myeloma Xenograft Model 59
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent antitumor activity in NOD-SCID mice bearing advanced tumors of human multiple myeloma. 48
THE COMBINATION OF MEK INHIBITORS AND ARSENIC TRIOXIDE TRIGGERS IN VITRO AND IN VIVO SYNERGISTIC CYTOTOXICITY IN MULTIPLE MYELOMA THROUGH MULTIPLE SIGNALING PATHWAYS 42
Arsenic Trioxide (ATO) Interacts Synergistically with MEK Inhibitors to Induce Apoptosis in STI571-Resistant Bcr-Abl Mutants 41
Totale 9.051
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.137
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.137
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022375 0 10 0 14 12 16 63 72 20 34 18 116
2022/20231.154 138 121 92 86 102 121 5 67 372 14 28 8
2023/2024402 33 47 17 7 54 68 23 9 15 22 34 73
2024/20251.590 59 91 104 60 208 197 30 74 215 138 114 300
2025/20263.122 281 273 343 243 390 202 409 135 388 220 161 77
2026/2027200 66 134 0 0 0 0 0 0 0 0 0 0
Totale 9.051